Y-Mabs Therapeutics Inc [YMAB] stock prices are up 3.55% to $6.42 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The YMAB shares have gain 11.27% over the last week, with a monthly amount glided 4.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Y-Mabs Therapeutics Inc [NASDAQ: YMAB] stock has seen the most recent analyst activity on November 18, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $23. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on August 16, 2024, and set its price target to $20. On June 28, 2024, Truist initiated with a Buy rating and assigned a price target of $21 on the stock. Wedbush upgraded its rating to a Outperform and increased its price target to $13 on May 10, 2023. Guggenheim downgraded its rating to a Neutral. Morgan Stanley downgraded its rating to Underweight for this stock on January 27, 2023, but kept the price target unchanged to $4. In a note dated January 05, 2023, Cowen downgraded an Market Perform rating on this stock.
The stock price of Y-Mabs Therapeutics Inc [YMAB] has been fluctuating between $5.60 and $20.90 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Y-Mabs Therapeutics Inc [NASDAQ: YMAB] shares were valued at $6.42 at the most recent close of the market. An investor can expect a potential return of 273.83% based on the average YMAB price forecast.
Analyzing the YMAB fundamentals
The Y-Mabs Therapeutics Inc [NASDAQ:YMAB] reported sales of 84.55M for trailing twelve months, representing a drop of -9.74%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.16 points at the first support level, and at 5.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.62, and for the 2nd resistance point, it is at 6.83.
Ratios To Look Out For
It’s worth pointing out that Y-Mabs Therapeutics Inc [NASDAQ:YMAB]’s Current Ratio is 3.92. Also, the Quick Ratio is 3.54, while the Cash Ratio stands at 2.69. Considering the valuation of this stock, the price to sales ratio is 3.40, the price to book ratio is 3.11.
Transactions by insiders
Recent insider trading involved Gad Thomas, CHIEF BUSINESS OFFICER, that happened on Sep 13 ’24 when 65000.0 shares were sold. CHIEF BUSINESS OFFICER, Gad Thomas completed a deal on Sep 16 ’24 to sell 30000.0 shares. Meanwhile, Officer Thomas Gad bought 100000.0 shares on Sep 13 ’24.
